Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry. Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab operations, optimize resources and expedite care.

Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo

Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. Thomas Schinecker welcomed positive early stage trial results from its two weight loss drug candidates as showing "best in disease potential.

Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results

Roche on Thursday raised its full-year earnings guidance, driven by high demand for newer drugs such as eye medicine Vabysmo.

Roche lifts 2024 profit guidance on drug sales

Roche CEO Thomas Schinecker: “Our strong sales growth in the first half of 2024 reflects the high demand for our innovative medicines and diagnostics. In the second quarter, we saw an acceleration of our growth momentum as Group sales were no longer impacted by the decline in COVID-19 sales, resulting in very strong sales growth for the Group. Based on our strong half-year results, we are raising our earnings outlook for the full year.

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised

Roche's CT-996 pill could be a promising oral therapy to help individuals lose weight. Roche also has another injectable obesity drug in its pipeline that could potentially be best in class.

Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?

Roche's shares rose after positive phase 1 results of oral GLP-1 agonist CT-996 in obese subjects. CT-996 demonstrated impressive weight reduction in 4 weeks, raising the efficacy bar for oral GLP-1 agonists. We need to see detailed safety and tolerability data of CT-996 and CT-388 for greater confidence in Roche's ability to compete in the obesity market.

Roche Is Raising The Efficacy Bar For The Oral GLP-1 Drug Class

Roche's latest data update indicates one of its weight-loss programs is doing well. It has more than enough resources to bring its candidate to the market.

This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?

The stock price of Roche (OTCMKTS: RHHBY) is up 10% in a week, compared to around a 10% fall for its peer Eli Lilly stock (NYSE: LLY) over this period. The rise in Roche stock in recent days can primarily be attributed to the positive data for phase one clinical trial of its experimental obesity drug – CT-996.

Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?

Pfizer

Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.

Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche

Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.

Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- #Cardiology--HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer.

HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer

Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes.1-4 Susvimo is the first and only refillable eye implant that provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform.5 The results build on the primary one-year analyses of the Pagoda and Pavilion studies, with Susvimo demonstrating sustained efficacy over two years and safety consistent with the known safety profile for Susvimo in people with DME and DR.6-9 Detailed results were presented at the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden.

New data for Roche's Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes. Susvimo is the first and only refillable eye implant that provides continuous delivery of a cus.

New Data for Genentech's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Roche's Genentech subsidiary is developing a pill-based diabetes and weight loss drug called CT-996. The new GLP-1 drug is in phase 1 clinical trials and saw patients losing 7% of their weight in four weeks.

Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo® (faricimab-svoa) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years. Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair si.

Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study.1 The study met all primary endpoints, showing that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years.2 Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair sight, and allow extended time between treatments in people with DME.2 These data were presented in a late-breaking oral presentation at The American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden.2

Roche's Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and Novo Nordisk (NVO) lower Wednesday.

Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise

Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.

Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug

Eli Lilly

Novo Nordisk

The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roche's new pill had shown promise in early-stage clinical trials.

Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?

Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.

Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk

Shares of Swiss drugmaker Roche rallied on Wednesday after the company's early-stage trial of an oral weight-loss drug showed it had promise.

Roche shares jump on drugmaker's early-stage data on weight-loss drug

Shares of Swiss pharma giant Roche climbed Wednesday after it reported promising results for an experimental weight loss pill, part of a cohort of hopeful competitors racing to challenge Novo Nordisk and Eli Lilly in the burgeoning diabetes and obesity drug market amid growing evidence the drugs can treat many other health conditions like kidney disease and sleep apnea.

Roche Climbs As Once-Daily Weight Loss Pill Shows Promise

Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks.

Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche

Roche said on Wednesday that its CT-996, a GLP-1 receptor agonist to treat obesity and type 2 diabetes, has had positive results in phase one of its clinical trial.

Roche reports positive early results in CT-966 obesity drug trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.1 The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinical.

News for Roche Holding AG Stock (RHHBY)